Advertise on podcast: Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology

An international expert panel utilized a modified Delphi process to establish practical consensus recommendations for assessing, monitoring, and managing brentuximab vedotin-induced peripheral neuropathy in patients with lymphoma. The resulting guidelines emphasize comprehensive baseline risk profiling, routine evaluation using validated tools like the Total Neuropathy Score, and prompt intervention for escalating symptoms to minimize nerve damage. Additionally, the study highlights the importance of personalized dose modifications, shared decision-making, and multidisciplinary support—including physical therapy and psychological care—to preserve patients' overall quality of life while maintaining therapeutic efficacy.

The reviewed literature examines the neurological complications associated with various tick-transmitted infections across North America and Eurasia. Although many tick-borne illnesses produce generalized, non-specific symptoms, certain pathogens possess the ability to breach the blood-brain barrier and cause true neuroinvasive disease. Specifically, infections such as Lyme disease, human monocytic ehrlichiosis, and Borrelia miyamotoi can occasionally result in meningitis or peripheral nerve involvement. Conversely, viral pathogens like Powassan virus and tick-borne encephalitis virus frequently trigger severe encephalitis and carry a high risk of long-term neurological impairment. Ultimately, the publication highlights the critical differences between systemic inflammation, common headaches, and genuine central nervous system infections to improve clinical diagnosis and management.

Monoclonal gammopathy of clinical significance (MGCS) is an overarching classification for non-malignant disorders directly caused by monoclonal proteins produced during clonal plasma cell proliferative disorders. These conditions encompass organ-specific diseases affecting the renal, neurological, cutaneous, and ocular systems, as well as complex multi-system syndromes like POEMS and Schnitzler syndrome. Because diagnosis often requires establishing a precise causal link between the protein and organ damage, clinicians must carefully differentiate true MGCS from coincidental associations. Management strategies typically focus on eradicating the underlying pathogenic clone or limiting the detrimental effects of the monoclonal proteins to halt disease progression.

Canada achieved nationwide implementation of newborn screening for spinal muscular atrophy in August 2024, establishing a standardized public health approach across all provinces and territories. A cross-sectional survey of provincial laboratory directors evaluated over 1.5 million screened infants to determine national birth prevalence and catalog testing methodologies. The calculated birth prevalence for the condition stood at approximately 1 in 12,524 live births, with survival motor neuron 2 gene copy numbers aligning closely with international proportions. Despite universal screening implementation, significant interprovincial variability persists regarding laboratory testing protocols, reporting practices, and the timing of results availability during initial family contact. Furthermore, inequities remain in the regional reimbursement of disease-modifying therapies, particularly affecting newborns diagnosed with four copies of the modifier gene despite growing expert consensus favoring early treatment.

POEMS syndrome is a life-threatening, multi-system disorder driven by an underlying plasma cell neoplasm, characterized by mandatory major criteria such as polyneuropathy and a clonal plasma cell disorder. Diagnosis requires a careful combination of clinical evaluations, radiographic bone assessments, bone marrow biopsies, and elevated vascular endothelial growth factor (VEGF) levels. Because the condition's pathogenesis remains poorly understood, risk stratification relies primarily on the patient's clinical phenotype and specific prognostic indicators like age and renal function. Treatment strategies are generally risk-adapted, utilizing localized irradiation for dominant solitary plasmacytomas or systemic therapy—such as alkylator-based regimens, immunomodulatory drugs, and autologous stem cell transplantation—for disseminated bone marrow involvement. Emphasizing prompt recognition, supportive care, and clone-directed therapies yields the best outcomes for patients managing this complex and rare syndrome.

Two phase 3 clinical trials evaluated the efficacy and safety of oveporexton, an oral orexin receptor 2-selective agonist, for treating narcolepsy type 1 over a 12-week period. Participants receiving twice-daily oveporexton experienced significant improvements in mean sleep latency, excessive daytime sleepiness, and the weekly cataplexy rate compared to those on a placebo. While adverse events such as increased urinary frequency and transient insomnia were more common in the treatment groups, most side effects were mild to moderate in severity. These findings confirm that addressing the underlying orexin deficiency successfully alleviates core narcolepsy symptoms and enhances overall quality of life.

This academic review proposes a unified spectrum model for multiple sclerosis (MS) that challenges traditional, rigid phenotype classifications like RRMS, SPMS, and PPMS. The authors argue that disability often accumulates through progression independent of relapse activity (PIRA) and "smouldering" disease processes, which frequently occur silently long before a formal progressive diagnosis. By integrating the role of neurologic reserve and biological ageing, the text explains how the clinical transition to progressive states reflects a declining capacity to compensate for ongoing tissue injury rather than a brand-new disease mechanism. This shift toward a biology-aware framework aims to facilitate earlier recognition of worsening and move treatment strategies beyond a simple focus on suppressing acute relapses. Ultimately, the source advocates for longitudinal, multidimensional monitoring to better address the continuous pathological evolution that shapes long-term neurological decline across the entire MS continuum.

This epiode is an extended version of the recently published episode on the examination and localization of eye movement disorders. The orginal paper details a comprehensive clinical framework for the examination and localization of eye movement disorders, emphasizing that the systematic bedside assessment serves as the primary tool for anatomical diagnosis. By distinguishing between supranuclear, nuclear, and infranuclear lesions, clinicians can categorize ocular motor dysfunction based on how specific eye movements, such as saccades or the vestibulo-ocular reflex, are impacted. The sources outline essential quantitative bedside tools—including prism cover tests and the HINTS battery—to differentiate between vascular, inflammatory, and degenerative causes. Detailed profiles of various conditions are provided, ranging from cranial nerve palsies and brainstem stroke syndromes to complex neuromuscular junction disorders like myasthenia gravis. Ultimately, the text illustrates how specific findings, such as pupillary involvement or fatigability, help narrow a wide differential into a precise neurological or structural diagnosis. This episode is based on a paper written exclusively for the Weekly Neurology Deep Dive Podcast by Amer A. Ghavanini MD PhD FRCPC.

This episode is a comprehensive review of a peper exploring the 2024 McDonald criteria, which represent a significant update to the global standards for diagnosing multiple sclerosis (MS). These revisions aim to facilitate earlier diagnosis and improve clinical outcomes by incorporating new paraclinical tools, such as optic nerve imaging, central vein sign, and kappa free light chains. For the first time, the criteria provide formal diagnostic pathways for asymptomatic individuals and those with atypical symptoms who exhibit characteristic MRI findings. The document also emphasizes strategies to avoid misdiagnosis, particularly in pediatric populations and older adults with vascular comorbidities. Furthermore, the authors address the practical challenges of global implementation, advocating for increased education and technological access in resource-limited settings.

This umbrella review evaluates the clinical efficacy and safety of two recently approved anti-amyloid antibodies, lecanemab and donanemab, for treating early-stage Alzheimer’s disease. By synthesizing data from eleven high-quality systematic reviews and meta-analyses, the authors conclude that these drugs successfully reduce brain amyloid burden and provide a statistically significant slowing of cognitive decline. However, the text highlights a critical concern: the observed cognitive benefits often fall below established clinically meaningful thresholds, suggesting that patients might not perceive a significant improvement in daily life. Furthermore, both treatments are associated with an increased risk of amyloid-related imaging abnormalities (ARIA), such as brain edema and hemorrhage, particularly in ApoEε4 gene carriers. Consequently, the source emphasizes that prescribing these therapies requires rigorous patient selection, careful monitoring through regular MRIs, and transparent communication regarding the modest expected outcomes. Ultimately, while these antibodies represent a significant pharmacological shift in dementia care, their benefits must be carefully weighed against potential safety risks and high financial costs.

This paper provides a comprehensive clinical framework for the examination and localization of eye movement disorders, emphasizing that the systematic bedside assessment serves as the primary tool for anatomical diagnosis. By distinguishing between supranuclear, nuclear, and infranuclear lesions, clinicians can categorize ocular motor dysfunction based on how specific eye movements, such as saccades or the vestibulo-ocular reflex, are impacted. The sources outline essential quantitative bedside tools—including prism cover tests and the HINTS battery—to differentiate between vascular, inflammatory, and degenerative causes. Detailed profiles of various conditions are provided, ranging from cranial nerve palsies and brainstem stroke syndromes to complex neuromuscular junction disorders like myasthenia gravis. Ultimately, the text illustrates how specific findings, such as pupillary involvement or fatigability, help narrow a wide differential into a precise neurological or structural diagnosis. This episode is based on a paper written exclusively for the Weekly Neurology Deep Dive Podcast by Amer A. Ghavanini MD PhD FRCPC.

This comprehensive review examines the evolution and clinical potential of liquid biopsy, a non-invasive diagnostic method that analyzes biomarkers within bodily fluids. The text classifies primary biomarkers such as circulating tumor DNA, intact tumor cells, and extracellular vesicles, while detailing the high-sensitivity technologies like digital PCR and next-generation sequencing used to detect them. In oncology, the authors highlight how these tools facilitate early cancer screening, the prediction of therapeutic responses, and the real-time monitoring of minimal residual disease or drug resistance. The scope extends beyond cancer to include applications in reproductive medicine, organ transplantation, and neurological disorders. Finally, the researchers address current implementation hurdles, such as the need for standardized protocols, and identify artificial intelligence as a key driver for future clinical integration.

This systematic review and meta-analysis evaluates the effectiveness and safety of therapeutic plasma exchange (TPE) for treating autoimmune neurological diseases (ANDs). By analyzing 38 studies involving 2,199 patients, the research indicates that TPE leads to a high rate of clinical improvement across various conditions, including Guillain-Barré syndrome and myasthenia gravis. While age appears to influence the success rate—with younger patients showing better responses than those over 60—geographic region and specific disease types do not show statistically significant differences in efficacy. The study finds an all-cause hospital mortality rate of 4%, though these deaths are largely attributed to the progression of the underlying disease rather than the procedure itself. Common but manageable adverse events identified include hypotension, coagulation disorders, and infections. Ultimately, the authors conclude that TPE is a safe and beneficial intervention, though they call for more rigorous, multicenter trials to refine treatment protocols.

Parsonage-Turner syndrome, also known as neuralgic amyotrophy, is a frequently misdiagnosed peripheral nerve disorder characterized by sudden, intense shoulder pain followed by muscle weakness and atrophy. While historically considered a rare and temporary condition, contemporary research reveals it is far more prevalent and can cause long-term disability and persistent fatigue. The condition is believed to be immune-mediated, often triggered by infections, physical trauma, or genetic predispositions, specifically involving the SEPT9 mutation. Diagnosis is primarily clinical but is increasingly supported by advanced imaging, such as ultrasound and MRI, which can detect unique nerve constrictions. While corticosteroids may offer early pain relief, long-term management focuses on specialized rehabilitation and, in severe cases, surgical intervention to address structural nerve damage. These updated insights emphasize that early recognition is vital for improving patient outcomes and preventing chronic functional loss. This episode is based on a paper written exclusively for the Weekly Neurology Deep Dive Podcast by Amer A. Ghavanini MD PhD FRCPC.

This clinical review examines the neurological complications associated with Merkel cell carcinoma (MCC), distinguishing between immune-mediated paraneoplastic syndromes and direct metastatic involvement. The text highlights that Lambert–Eaton myasthenic syndrome (LEMS) is the most frequent paraneoplastic manifestation and often appears before the cancer is officially diagnosed. Diagnostic protocols emphasize the use of paired serum and CSF antibody testing, specifically looking for VGCC, anti-Hu, and neurofilament antibodies to identify underlying malignancy. Management of these conditions primarily focuses on oncologic control, utilizing immune checkpoint inhibitors and stereotactic radiosurgery to improve patient outcomes. The author stresses the importance of differentiating structural brain disease from autoimmune reactions, as the therapeutic strategies for each differ significantly. Ultimately, the source provides a comprehensive framework for clinicians to identify, stage, and treat the complex nervous system interactions of this rare skin cancer. This episode is based on a paper written exclusively for the Weekly Neurology Deep Dive Podcast by Amer A. Ghavanini MD PhD FRCPC.